Integra Therapeutics is one of the biotech companies that the Spanish Bioindustry Association (AseBio) has chosen for its new campaign #VidaALaBiotecnología, which aims to value the capacity of this strategic sector to grow, consolidate itself and unfold its potential in Spain.

Biotechnology is crucial in responding to the challenges facing Europe thanks to its ability to transform and have an impact on areas like health, agriculture, food and the green transition.

The campaign was unveiled by AseBio CEO, Ion Arocena, during the BioSpain conference held last September in Barcelona.

Dr Avencia Sánchez-Mejías, CEO and co-founder of Integra Therapeutics, took part in one of the first acts to get under way, the #HistoriasQueDanVida: